Fexuprazan is under clinical development by Daewoong and currently in Phase III for Reflux Esophagitis (Gastroesophageal Reflux Disease). According to GlobalData, Phase III drugs for Reflux Esophagitis (Gastroesophageal Reflux Disease) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Fexuprazan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fexuprazan overview

Fexuprazan (Fexuprazan Hydrochloride, Fexuclu, Abcito) is a P-CAB (Potassium-Competitive) Acid Blocker). It is formulated as film-coated tablets for oral route of administration. It is indicated for the treatment of erosive gastroesophageal reflux disease.

Fexuprazan (DWP-14012) is under development for the treatment of acute or chronic gastritis, gastric ulcers, erosive esophagitis and erosive gastroesophageal reflux disease. It is a small molecule which is administered by oral route in the form of tablet and as injection form. It acts by targeting the acid pump, H+/K(+) ATPase. The drug candidate is a potassium-competitive acid blocker (P-CAB).

Daewoong overview

Daewoong is an investment holding company. The company operates its business through its subsidiaries including Daewoong Pharmaceutical Co., Ltd and R&P Korea Co., Ltd, which are engaged in the manufacture of pharmaceuticals; Daewoong Life Science Co., Ltd., which is engaged in the food processing business; Daewoong Management Development Institute, which provides enterprise education solutions; IDS&TRUST Co., Ltd., which is engaged in the information technology (IT) solution business; and Deawoong Bio Co., Ltd., which offers pharmaceutical raw materials. Daewoong is headquartered in Seoul, South Korea.

For a complete picture of Fexuprazan’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.